Medical Professionals

Developing Novel Immunotherapy Treatments

Atara Biotherapeutics is a leading off-the-shelf T-cell immunotherapy company developing novel treatments for patients with cancer, autoimmune and viral diseases. Our commitment is to make every effort to support patients in need of treatment options.

Our Clinical Studies

Our clinical studies evaluate the potential of our investigational treatments in a well-defined patient population with eligibility criteria that allow for appropriate assessment of safety and clinical effect. If you are interested in learning more about our ongoing clinical studies, please contact us at  ClinicalStudies@atarabio.com.

Expanded Access Programs

“Expanded Access” is a pathway to use unapproved treatments outside of clinical trials, usually for severe or life-threatening conditions.

At this time, Atara does not have any active Expanded Access Protocols nor do we provide access to our investigational products on an Expanded Access basis, and participation in our trials is the only way to access our investigational therapies.

We encourage physicians and patients interested in our investigational therapies to learn more about our ongoing studies by visiting www.clinicaltrials.gov and searching for Atara Biotherapeutics. If you are a physician interested in learning more about our investigational cell therapies or participating in our clinical trials, please submit a request to ClinicalStudies@atarabio.com.

Clinical Studies

Clinical Studies Aimed at Addressing Unmet Medical Needs

There is a high unmet medical need for additional effective immunotherapies. We believe our novel treatments currently in clinical development have the potential to change the way we approach certain life-threatening diseases.

Clinical Studies Aimed at Addressing Unmet Medical Needs

Requests for Expanded Access

Atara does not have an expanded access program at this time and participation in our clinical study is the only way to access our investigational therapies.
View Policy